Analysts' ratings for BrightSpring Health (NASDAQ:BTSG) over the last quarter vary from bullish to bearish, as provided by 11 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 6 | 3 | 1 | 0 | 0 |
Analysts have set 12-month price targets for BrightSpring Health, revealing an average target of $16.77, a high estimate of $26.00, and a low estimate of $11.50. Observing a downward trend, the current average is 18.2% lower than the prior average price target of $20.50.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis of recent analyst actions unveils how financial experts perceive BrightSpring Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stephen Baxter | Wells Fargo | Raises | Overweight | $16.00 | $15.00 |
| Sidharth Sahoo | HSBC | Announces | Buy | $13.00 | - |
| Jamie Perse | Goldman Sachs | Lowers | Buy | $23.00 | $26.00 |
| Pito Chickering | Deutsche Bank | Announces | Hold | $11.50 | - |
| Whit Mayo | Leerink Partners | Announces | Outperform | $15.00 | - |
| Joanna Gajuk | B of A Securities | Announces | Buy | $14.00 | - |
| A.J. Rice | UBS | Announces | Buy | $15.00 | - |
| Stephen Baxter | Wells Fargo | Announces | Overweight | $15.00 | - |
| Brian Tanquilut | Jefferies | Announces | Buy | $18.00 | - |
| Erin Wright | Morgan Stanley | Announces | Overweight | $18.00 | - |
| Jamie Perse | Goldman Sachs | Announces | Buy | $26.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BrightSpring Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of BrightSpring Health compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for BrightSpring Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BrightSpring Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on BrightSpring Health analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into BrightSpring Health's Background
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Service. and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
Breaking Down BrightSpring Health's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining BrightSpring Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.5% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: BrightSpring Health's net margin excels beyond industry benchmarks, reaching -0.28%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BrightSpring Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.07%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): BrightSpring Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.12%, the company may face hurdles in achieving optimal financial performance.
Debt Management: BrightSpring Health's debt-to-equity ratio stands notably higher than the industry average, reaching 6.28. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.